一项小型研究发现,在标准治疗中添加了高级Ewing sarcoma的儿童,pazopanib可促进其生存。 A small study finds pazopanib boosts survival in children with advanced Ewing sarcoma when added to standard treatment.

一项小型研究显示,pazopanib是一种最初用于肾癌的药物,如果与标准治疗相结合,可能会大大改善患有高级Ewing sarrcoma的儿童的存活率。 A small study shows pazopanib, a drug originally for kidney cancer, may significantly improve survival for children with advanced Ewing sarcoma when combined with standard treatments. 在11名病人中,86%活了两年,68%没有病情发展,远远超过了典型的结果。 Among 11 patients, 86% survived two years, and 68% showed no disease progression, far exceeding typical outcomes. 阻断肿瘤血管生长的这种药物是经过精心培育的,其副作用很小。 The drug, which blocks tumor blood vessel growth, was well-tolerated with minimal side effects. 波兰华沙妇幼研究所的Anna Raciborska领导的研究人员认为结果很有希望,但强调由于该病的罕见性,需要进行规模更大、受控制的试验。 Researchers led by Anna Raciborska of Poland’s Warsaw Mother and Child Institute call the results promising but stress the need for larger, controlled trials due to the disease’s rarity.